OnKure hires chief medical officer as drug trials loom
BOULDER — OnKure Inc., a precision oncology company, recently hired Samuel Agresta as its chief medical officer.
Agresta, who previously held the same role at Foghorn Therapeutics Inc., joins OnKure as the company gears up to begin clinical trials for its leading cancer therapy OKI-219, a selective PI3K alpha H1047R inhibitor.
“The development of highly safe and effective treatments for patients who suffer from breast cancer is important work,” Agresta said in a news release.
SPONSORED CONTENT
OnKure Inc., a precision oncology company, recently hired Samuel Agresta as its chief medical officer.
Related Posts
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…